FDA to Review Abuse-Deterrent Oxycodone Capsule

FDA to Review Abuse-Deterrent Oxycodone Capsule In June, the FDA will discuss the New Drug Application for Remoxy ER at an Advisory Committee meeting. Remoxy ER is a 12-hour, abuse-deterrent, extended-release oxycodone in a capsule formulation.1 The capsule contains a sticky, thick, high-viscosity formulation to deter unapproved drug administration routes, including injection, smoking or snorting.... [Read More]
Source: The Rheumatologist - Category: Rheumatology Authors: Tags: Drug Updates adalimumab NSAIDs Oxycodone plaque psoriasis tildrakizumab-asmn Source Type: research